In ACC, therapeutic inhibition of MDM2-p53 was shown to decrease the CSC fraction via apoptosis as well as an increase in cells within the G1 phase of the cell cycle in vitro and in vivo (88). The gene discussed is TP53; the disease is adrenal cortex carcinoma.